Safety Escalating Repeat IV, in Stroke Patients "MAG111539"

Completed

Phase 2 Results

Summary of Purpose

The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 17 October 2017.

8 Jul 2009 29 Jan 2009 31 Jan 2011 31 Jan 2011 1 Sep 2017 31 Jul 2017
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Single Blind (Subject)
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment

Contacts

  • Lori Enney anti-MAG CMT Leader Stroke & ALS Clinical Development Neurosciences MDC MAI-C.3640.3A; RTP Tel) 919-483-1420 Fax) 919-483-6763 Cell) 919-423-2977 e-mail) Lori.A.Enney@gsk.com

    Lori.A.Enney@gsk.com